Alternative models for carcinogenicity testing

被引:42
作者
Cohen, SM
Robinson, D
MacDonald, J
机构
[1] Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Nebraska Med Ctr 983135, Omaha, NE 68198 USA
[2] Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Nebraska Med Ctr 983135, Omaha, NE 68198 USA
[3] Int Life Sci Inst, Hlth & Enviornm Sci Inst, Washington, DC 20005 USA
[4] Schering Plough Res Inst, Kenilworth, NJ 07033 USA
关键词
carcinogenesis testing; hazard identification; risk assessment; rodent bioassay; transgenic models;
D O I
10.1093/toxsci/64.1.14
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
The International Conference on Harmonisation Expert Working Group on Safety suggested that under certain circumstances, data from alternative assays could be used in safety evaluation in place of a second bioassay. Several alternatives were discussed. Six of these models were evaluated in a collaborative effort under the auspices of the Health and Environmental Sciences Institute (HESI) branch of the International Life Sciences Institute (ILSI). Standard protocols, pathology review, and statistical evaluations were developed. Twenty-one chemicals were evaluated, including genotoxic, nongenotoxic, carcinogenic, and noncarcinogenic chemicals. The models that were evaluated included the p53(+/-) heterozygous knockout mouse, the rasH2 transgenic mouse, the TgAC transgenic mouse (dermal and oral administration), the homozygous XPA knockout and the XPA/p53 knockout mouse models. Also evaluated were the neonatal mouse models and the Syrian Hamster Embryo (SHE) transformation assay. The results of this comprehensive study suggest that some of these models might be useful in hazard identification if used in conjunction with information from other sources in a weight of evidence, integrated analysis approach to risk assessment.
引用
收藏
页码:14 / 19
页数:6
相关论文
共 17 条
[1]   RODENT CARCINOGENICITY BIOASSAY - PAST, PRESENT, AND FUTURE [J].
BOORMAN, GA ;
MARONPOT, RR ;
EUSTIS, SL .
TOXICOLOGIC PATHOLOGY, 1994, 22 (02) :105-111
[2]  
CARMICHAEL PL, IN PRESS TOXICOL PAT
[3]   Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans? [J].
Cattley, RC ;
DeLuca, J ;
Elcombe, C ;
Fenner-Crisp, P ;
Lake, BG ;
Marsman, DS ;
Pastoor, TA ;
Popp, JA ;
Robinson, DE ;
Schwetz, B ;
Tugwood, J ;
Wahli, W .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 1998, 27 (01) :47-60
[4]  
Cohen SM, 1999, MICROBES AND MALIGNANCY, P89
[5]   Carcinogenicity testing and the evaluation of regulatory requirements for pharmaceuticals [J].
Contrera, JF ;
Jacobs, AC ;
DeGeorge, JJ .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 1997, 25 (02) :130-145
[6]  
DAVIES TS, 1995, J AM COLL TOXICOL, V14, P90, DOI 10.3109/10915819509008684
[7]   Neonatal mouse assay for tumorigenicity: Alternative to the chronic rodent bioassay [J].
Flammang, TJ ;
VonTungeln, LS ;
Kadlubar, FF ;
Fu, PP .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 1997, 26 (02) :230-240
[8]   Use of transgenic animals for carcinogenicity testing: Considerations and implications for risk assessment [J].
Gulezian, D ;
Jacobson-Kram, D ;
McCullough, CB ;
Olson, H ;
Recio, L ;
Robinson, D ;
Storer, R ;
Tennant, R ;
Ward, JM ;
Neumann, DA .
TOXICOLOGIC PATHOLOGY, 2000, 28 (03) :482-499
[9]  
JOHANSSON S, 1974, CANCER-AM CANCER SOC, V33, P743, DOI 10.1002/1097-0142(197403)33:3<743::AID-CNCR2820330321>3.0.CO
[10]  
2-M